Iradimed (NASDAQ:IRMD - Get Free Report) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a report issued on Tuesday.
Separately, Roth Mkm restated a "buy" rating and set a $72.00 target price (up from $60.00) on shares of Iradimed in a research note on Friday, February 14th.
Get Our Latest Research Report on Iradimed
Iradimed Stock Performance
Shares of NASDAQ IRMD traded down $0.18 during mid-day trading on Tuesday, reaching $52.21. The company had a trading volume of 30,453 shares, compared to its average volume of 41,156. Iradimed has a one year low of $40.18 and a one year high of $63.29. The business's 50-day simple moving average is $57.38 and its 200 day simple moving average is $53.15. The firm has a market cap of $661.66 million, a price-to-earnings ratio of 34.81 and a beta of 0.82.
Iradimed (NASDAQ:IRMD - Get Free Report) last released its earnings results on Thursday, February 13th. The medical equipment provider reported $0.40 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.05). Iradimed had a net margin of 26.26% and a return on equity of 24.12%. The firm had revenue of $19.39 million during the quarter, compared to the consensus estimate of $19.09 million. On average, sell-side analysts anticipate that Iradimed will post 1.66 EPS for the current year.
Hedge Funds Weigh In On Iradimed
Several institutional investors have recently added to or reduced their stakes in IRMD. R Squared Ltd acquired a new stake in Iradimed in the fourth quarter worth $30,000. US Bancorp DE boosted its holdings in Iradimed by 476.6% in the fourth quarter. US Bancorp DE now owns 617 shares of the medical equipment provider's stock worth $34,000 after acquiring an additional 510 shares in the last quarter. Huntington National Bank raised its position in shares of Iradimed by 51.3% during the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider's stock worth $75,000 after purchasing an additional 504 shares during the period. Gladius Capital Management LP lifted its stake in shares of Iradimed by 126.6% in the third quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider's stock valued at $87,000 after buying an additional 965 shares in the last quarter. Finally, Quantbot Technologies LP grew its holdings in shares of Iradimed by 83.0% during the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider's stock valued at $117,000 after buying an additional 1,052 shares during the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.
About Iradimed
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
See Also
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
